National Bank of Canada
PSTX

National Bank of Canada’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

National Bank of Canada’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,500
Closed -$5.07K – 2951
2023
Q4 		$5.07K Buy
+1,500
New +$3.86K ﹤0.01% 2305

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

National Bank of Canada's PSTX Position: Q1 2024 in Review

National Bank of Canada sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2024, closing a stake of 1,500 shares — an estimated $5.07K sold.

National Bank of Canada first reported a position in PSTX in Q4 2023 and held it in 1 quarter. The position peaked at $5.07K in Q4 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q1 2024.

  • National Bank of Canada reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • National Bank of Canada sold 1,500 Poseida Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $5.07K.
  • National Bank of Canada first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • National Bank of Canada's Poseida Therapeutics, Inc. Common Stock position peaked at $5.07K in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2024.

Based on National Bank of Canada's 13F filing for Q1 2024, filed 13 May 2024.